Advertisement

Analytical and Bioanalytical Chemistry

, Volume 406, Issue 16, pp 3815–3829 | Cite as

GC-MS and LC-(high-resolution)-MS n studies on the metabolic fate and detectability of camfetamine in rat urine

  • Jessica Welter
  • Pierce Kavanagh
  • Hans H. MaurerEmail author
Paper in Forefront

Abstract

Camfetamine (N-methyl-3-phenyl-norbornan-2-amine; CFA) belongs as amphetamine-type stimulant to the so-called new psychoactive substances. CFA is an analogue of fencamfamine, an appetite suppressant developed in the 1960s. The described effects of CFA are slight stimulation and increased vigilance and the side effects are tachycardia, paranoia, and sleeplessness. The aims of the presented work were to study the metabolic fate and the detectability of CFA in urine and to elucidate which cytochrome-P450 (CYP) isoenzymes are involved in the main metabolic steps. For metabolism studies, rat urine samples were isolated by solid-phase extraction without and after enzymatic cleavage of conjugates. The phase I metabolites were separated and identified after/without acetylation by gas chromatography-mass spectrometry (GC-MS) and/or liquid chromatography-high resolution-linear ion trap mass spectrometry (LC-HR-MS n ), respectively, and the phase II metabolites by LC-HR-MS n . From the identified metabolites, the following main metabolic pathways were deduced: N-demethylation, aromatic mono or bis-hydroxylation followed by methylation of one hydroxy group, hydroxylation of the norbornane ring, combination of these steps, and glucuronidation and/or sulfation of the hydroxy metabolites. The N-demethylation was catalyzed by CYP2B6, CYP2C19, CYP2D6, and CYP3A4, the aromatic hydroxylation by CYP2C19 and CYP2D6, and the aliphatic hydroxylation was catalyzed by CYP1A2, CYP2B6, CYP2C19, and CYP3A4. Finally, the intake of a common user’s dose of CFA could be confirmed in rat urine using the authors’ GC-MS and the LC-MS n standard urine screening approaches via CFA and several metabolites, with the hydroxy-aryl CFA and the corresponding glucuronide being the most abundant.

Figure. a

Keywords

Designer drugs Camfetamine Metabolism Cytochrome-P450 GC-MS LC-(HR)-MSn 

Notes

Acknowledgments

The authors thank Julia Dinger, Golo M. Meyer, Markus R. Meyer, Julian A. Michely, Carsten Schröder, Gabriele Ulrich, Armin A. Weber, and Carina S. D. Wink for support and/or helpful discussion.

References

  1. 1.
    DeLucia R, Bernardi MM, Scavone C, Aizenstein ML (1984) On the mechanism of central stimulation action of fencamfamine. Gen Pharmacol 15:407–410CrossRefGoogle Scholar
  2. 2.
    DeLucia R, Planeta CS, Scavone C, Aizenstein ML (1987) Reduction of food intake by fencamfamine in rats. Gen Pharmacol 18:21–23CrossRefGoogle Scholar
  3. 3.
    Planeta CS, Scavone C, De LR, Aizenstein ML (1987) Behavioural effects of long-term administration of fencamfamine: neurochemical implications. Gen Pharmacol 18:347–349CrossRefGoogle Scholar
  4. 4.
    Planeta CS, Aizenstein ML, Scavone C, DeLucia R (1989) Behavioral and neurochemical effects of fencamfamine on rats: a chronobiologic approach. Chronobiol Int 6:313–320CrossRefGoogle Scholar
  5. 5.
    Planeta CS, Aizenstein ML, DeLucia R (1995) Reinforcing properties of fencamfamine: involvement of dopamine and opioid receptors. Pharmacol Biochem Behav 50:35–40CrossRefGoogle Scholar
  6. 6.
    Kuczenski R, Segal DS, Aizenstein ML (1991) Amphetamine, cocaine, and fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and accumbens dopamine dynamics. J Neurosci 11:2703–2712Google Scholar
  7. 7.
    Delbeke FT, Debackere M (1992) Disposition of human drug preparations in the horse. II. Orally administered fencamfamine. J Pharm Biomed Anal 10:651–656CrossRefGoogle Scholar
  8. 8.
    Delbeke FT, Debackere M (1981) Detection and metabolism of fencamfamine and the influence of acetazolamide on its urinary excretion. Biopharm Drug Dispos 2:17–30CrossRefGoogle Scholar
  9. 9.
    Kavanagh P, Angelov D, O'Brien J, Power JD, McDermott SD, Talbot B, Fox J, O'Donnell C, Christie R (2013) The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine). Drug Test Anal 5:247–253CrossRefGoogle Scholar
  10. 10.
    Maurer HH, Pfleger K, Weber AA (2011) Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. Wiley-VCH, WeinheimGoogle Scholar
  11. 11.
    Welter J, Meyer MR, Wolf E, Weinmann W, Kavanagh P, Maurer HH (2013) 2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 405:3125–3135CrossRefGoogle Scholar
  12. 12.
    Welter J, Meyer MR, Kavanagh P, Maurer HH (2014) Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MSn. Anal Bioanal Chem 406:1957–1974CrossRefGoogle Scholar
  13. 13.
    Meyer GMJ, Meyer MR, Wissenbach DK, Maurer HH (2013) Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from Glaucium flavum (Papaveraceae), in rat urine using GC-MS, LC-MSn and LC-high-resolution MSn. J Mass Spectrom 48:24–41CrossRefGoogle Scholar
  14. 14.
    Meyer MR, Schmitt S, Maurer HH (2013) Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-HR-MS/MS. J Mass Spectrom 48:243–249CrossRefGoogle Scholar
  15. 15.
    Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Development of the first metabolite-based LC-MSn urine drug screening procedure—exemplified for antidepressants. Anal Bioanal Chem 400:79–88CrossRefGoogle Scholar
  16. 16.
    Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH (2011) Drugs of abuse screening in urine as part of a metabolite-based LC-MS(n) screening concept. Anal Bioanal Chem 400:3481–3489CrossRefGoogle Scholar
  17. 17.
    Maurer HH, Pfleger K, Weber AA (2011) Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants, and their Metabolites. Wiley-VCH, WeinheimGoogle Scholar
  18. 18.
    Ewald AH, Ehlers D, Maurer HH (2008) Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 390:1837–1842CrossRefGoogle Scholar
  19. 19.
    Meyer MR, Peters FT, Maurer HH (2010) Automated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine. Clin Chem 56:575–584CrossRefGoogle Scholar
  20. 20.
    Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225–1233CrossRefGoogle Scholar
  21. 21.
    McLafferty FW, Turecek F (1993) Interpretation of Mass Spectra. University Science Books, Mill ValleyGoogle Scholar
  22. 22.
    Smith RM, Busch KL (1999) Understanding Mass Spectra—A Basic Approach. Wiley, New YorkGoogle Scholar
  23. 23.
    de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K (1992) Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG commission for clinical toxicological analysis, special issue of the TIAFT bulletin). VCH Publishers, WeinheimGoogle Scholar
  24. 24.
    Kovats E (1958) Gaschromatographische Charakterisierung organischer Verbindungen. Teil 1. Retentionsindices aliphatischer Halogenide, Alkohole, Aldehyde, und Ketone. Helv Chim Acta 41:1915–1932CrossRefGoogle Scholar
  25. 25.
    Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem 405:6307–6321CrossRefGoogle Scholar
  26. 26.
    Sharma V, McNeill JH (2009) To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 157:907–921CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Jessica Welter
    • 1
  • Pierce Kavanagh
    • 2
  • Hans H. Maurer
    • 1
    Email author
  1. 1.Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and ToxicologySaarland UniversityHomburgGermany
  2. 2.Department of Pharmacology and TherapeuticsTrinity Centre for Health and Sciences, St. James’s HospitalDublin 8Ireland

Personalised recommendations